Recent studies indicate that humanized monoclonal antibodies against CD248 show a significant pre-clinical effect on the suppression of tumor progression partly through the reduction of membrane CD248 expression [47] and maybe because of the inhibition of cell-ECM interaction [16]; however, the beneficial effects on cancer patients with CD248 antibody treatment was limited [48, 49]. This evidence concerns the gene CD248 and cancer.